Detalhe da pesquisa
1.
Empagliflozin and Clinical Outcomes in Patients With Type 2 Diabetes Mellitus, Established Cardiovascular Disease, and Chronic Kidney Disease.
Circulation
; 137(2): 119-129, 2018 01 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-28904068
2.
Empagliflozin and Progression of Kidney Disease in Type 2 Diabetes.
N Engl J Med
; 375(4): 323-34, 2016 Jul 28.
Artigo
em Inglês
| MEDLINE | ID: mdl-27299675
3.
Empagliflozin and Kidney Function Decline in Patients with Type 2 Diabetes: A Slope Analysis from the EMPA-REG OUTCOME Trial.
J Am Soc Nephrol
; 29(11): 2755-2769, 2018 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-30314978
4.
Pooled analysis of Phase III trials indicate contrasting influences of renal function on blood pressure, body weight, and HbA1c reductions with empagliflozin.
Kidney Int
; 93(1): 231-244, 2018 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-28860019
5.
Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes.
N Engl J Med
; 373(22): 2117-28, 2015 11 26.
Artigo
em Inglês
| MEDLINE | ID: mdl-26378978
6.
Rationale, design, and baseline characteristics of the CArdiovascular safety and Renal Microvascular outcomE study with LINAgliptin (CARMELINA®): a randomized, double-blind, placebo-controlled clinical trial in patients with type 2 diabetes and high cardio-renal risk.
Cardiovasc Diabetol
; 17(1): 39, 2018 03 14.
Artigo
em Inglês
| MEDLINE | ID: mdl-29540217
7.
Empagliflozin and Cerebrovascular Events in Patients With Type 2 Diabetes Mellitus at High Cardiovascular Risk.
Stroke
; 48(5): 1218-1225, 2017 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-28386035
8.
Influence of common polymorphisms in the SLC5A2 gene on metabolic traits in subjects at increased risk of diabetes and on response to empagliflozin treatment in patients with diabetes.
Pharmacogenet Genomics
; 27(4): 135-142, 2017 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-28134748
9.
Linagliptin as add-on to empagliflozin and metformin in patients with type 2 diabetes: Two 24-week randomized, double-blind, double-dummy, parallel-group trials.
Diabetes Obes Metab
; 19(2): 266-274, 2017 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-27762093
10.
Heart failure outcomes with empagliflozin in patients with type 2 diabetes at high cardiovascular risk: results of the EMPA-REG OUTCOME® trial.
Eur Heart J
; 37(19): 1526-34, 2016 May 14.
Artigo
em Inglês
| MEDLINE | ID: mdl-26819227
11.
Metabolic consequences of acute and chronic empagliflozin administration in treatment-naive and metformin pretreated patients with type 2 diabetes.
Diabetologia
; 59(4): 700-8, 2016 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-26704626
12.
Renal hemodynamic effect of sodium-glucose cotransporter 2 inhibition in patients with type 1 diabetes mellitus.
Circulation
; 129(5): 587-97, 2014 Feb 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-24334175
13.
Effect of empagliflozin monotherapy on postprandial glucose and 24-hour glucose variability in Japanese patients with type 2 diabetes mellitus: a randomized, double-blind, placebo-controlled, 4-week study.
Cardiovasc Diabetol
; 14: 11, 2015 Jan 30.
Artigo
em Inglês
| MEDLINE | ID: mdl-25633683
14.
Safety, tolerability and effects on cardiometabolic risk factors of empagliflozin monotherapy in drug-naïve patients with type 2 diabetes: a double-blind extension of a Phase III randomized controlled trial.
Cardiovasc Diabetol
; 14: 154, 2015 Dec 23.
Artigo
em Inglês
| MEDLINE | ID: mdl-26701110
15.
The effect of empagliflozin on arterial stiffness and heart rate variability in subjects with uncomplicated type 1 diabetes mellitus.
Cardiovasc Diabetol
; 13: 28, 2014 Jan 29.
Artigo
em Inglês
| MEDLINE | ID: mdl-24475922
16.
Rationale, design, and baseline characteristics of a randomized, placebo-controlled cardiovascular outcome trial of empagliflozin (EMPA-REG OUTCOME™).
Cardiovasc Diabetol
; 13: 102, 2014 Jun 19.
Artigo
em Inglês
| MEDLINE | ID: mdl-24943000
17.
Pharmacokinetics of empagliflozin, a sodium glucose cotransporter 2 inhibitor, and simvastatin following co-administration in healthy volunteers.
Int J Clin Pharmacol Ther
; 52(11): 973-80, 2014 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-25161155
18.
Rationale, design and baseline characteristics of a 4-year (208-week) phase III trial of empagliflozin, an SGLT2 inhibitor, versus glimepiride as add-on to metformin in patients with type 2 diabetes mellitus with insufficient glycemic control.
Cardiovasc Diabetol
; 12: 129, 2013 Sep 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-24007456
19.
The sodium glucose cotransporter 2 inhibitor empagliflozin does not prolong QT interval in a thorough QT (TQT) study.
Cardiovasc Diabetol
; 12: 70, 2013 Apr 24.
Artigo
em Inglês
| MEDLINE | ID: mdl-23617452
20.
Pharmacokinetics of empagliflozin, a sodium glucose cotransporter-2 (SGLT2) inhibitor, and metformin following co-administration in healthy volunteers.
Int J Clin Pharmacol Ther
; 51(2): 132-40, 2013 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-23253948